William Blair healthcare research analysts believe the radiopharmaceutical industry represents one of the most compelling secular growth opportunities in biotechnology in the next three to five years. Defying the conventional belief that it remains a niche market, we are optimistic that the recent resurgence in investor and big pharma interest may continue to drive investment in the field.
Biotech analyst Andy Hsieh, Ph.D., provides his annual update on radiopharmaceuticals in Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals—Fourth Edition. In the latest edition, Hsieh focuses on the role of diagnostics, specifically in diagnosing Alzheimer’s disease. With more than 7 million Americans living with Alzheimer’s disease, advanced tools may help the field move toward routine genetic screening to identify patients who could benefit from initiating earlier treatment.
For more information on William Blair’s biotechnology research, contact us or your William Blair representative.